Omalizumab discontinuation in children with severe allergic asthma: An observational real‐life study

Allergy ◽  
2019 ◽  
Vol 74 (5) ◽  
pp. 999-1003 ◽  
Author(s):  
Antoine Deschildre ◽  
Juliette Roussel ◽  
Elodie Drumez ◽  
Rola Abou‐Taam ◽  
Cinthia Rames ◽  
...  
Keyword(s):  
Allergic Asthma ◽  
Real Life ◽  
Life Study ◽  
Severe Allergic Asthma ◽  
Real Life Study

scholarly journals Response to omalizumab in patients with severe allergic asthma: A real-life study

2017 ◽  
Vol 131 ◽  
pp. 109-113 ◽  
Author(s):  
Louise Zierau ◽  
Emil Schwarz Walsted ◽  
Simon Francis Thomsen ◽  
Vibeke Backer
Keyword(s):  
Allergic Asthma ◽  
Real Life ◽  
Life Study ◽  
Severe Allergic Asthma ◽  
Real Life Study

Real life study showing the epidemiological profile and adherence to treatment of patients with severe allergic asthma in use of omalizumab in the past year.

2018 ◽  
Author(s):  
Alcindo Cerci Neto ◽  
Olavo Franco Ferreira Filho ◽  
Fatima Mitsie Chibana ◽  
Marcos Ribeiro ◽  
Renato Kauffmann ◽  
...  
Keyword(s):  
Allergic Asthma ◽  
Real Life ◽  
Adherence To Treatment ◽  
Life Study ◽  
The Past ◽  
Severe Allergic Asthma ◽  
Real Life Study ◽  
Epidemiological Profile

scholarly journals Effectiveness of Omalizumab in Severe Allergic Asthma and Nasal Polyposis: A Real-Life Study

2020 ◽  
Vol 30 (1) ◽  
pp. 49-57 ◽  
Author(s):  
A Tiotiu ◽  
JP Oster ◽  
PR Roux ◽  
PL Nguyen Thi ◽  
G Peiffer ◽  
...  
Keyword(s):  
Allergic Asthma ◽  
Nasal Polyposis ◽  
Real Life ◽  
Life Study ◽  
Severe Allergic Asthma ◽  
Real Life Study

Predictors of response to therapy with omalizumab in patients with severe allergic asthma–a real life study

2017 ◽  
Author(s):  
Maria Kallieri ◽  
Andriana Papaioannou ◽  
Evgenia Papathanasiou ◽  
Polyxeni Dontsi ◽  
Spyridon Papiris ◽  
...  
Keyword(s):  
Allergic Asthma ◽  
Real Life ◽  
Response To Therapy ◽  
Life Study ◽  
Predictors Of Response ◽  
Severe Allergic Asthma ◽  
Real Life Study

Predictors of response to therapy with omalizumab in patients with severe allergic asthma – a real life study

2017 ◽  
Vol 129 (6) ◽  
pp. 598-604 ◽  
Author(s):  
Maria Kallieri ◽  
Andriana I. Papaioannou ◽  
Evgenia Papathanasiou ◽  
Polyxeni Ntontsi ◽  
Spyridon Papiris ◽  
...  
Keyword(s):  
Allergic Asthma ◽  
Real Life ◽  
Response To Therapy ◽  
Life Study ◽  
Predictors Of Response ◽  
Severe Allergic Asthma ◽  
Real Life Study

scholarly journals Omalizumab effectiveness in patients with severe allergic asthma according to blood eosinophil count: the STELLAIR study

2018 ◽  
Vol 51 (5) ◽  
pp. 1702523 ◽  
Author(s):  
Marc Humbert ◽  
Camille Taillé ◽  
Laurence Mala ◽  
Vincent Le Gros ◽  
Jocelyne Just ◽  
...  
Keyword(s):  
Allergic Asthma ◽  
Eosinophil Count ◽  
Response Rate ◽  
Real Life ◽  
Blood Eosinophil ◽  
Exacerbation Rate ◽  
Blood Eosinophil Count ◽  
Life Study ◽  
Severe Allergic Asthma ◽  
Blood Eosinophils

Omalizumab is a monoclonal anti-IgE antibody used to treat severe allergic asthma (SAA). The aim of the STELLAIR study was to determine the importance of pre-treatment blood eosinophil count as a predictive measure for response to omalizumab.This retrospective real-life study was conducted in France between December 2015 and September 2016 using medical records of SAA omalizumab-treated patients. Response to omalizumab was assessed by three criteria: physician evaluation, reduction of ≥40% in annual exacerbation rate and a combination of both. Response rate was calculated according to blood eosinophil count measured in the year prior to omalizumab initiation.872 SAA omalizumab-treated patients were included by 78 physicians (723 adults (age ≥18 years) and 149 minors (age 6–17 years)). Blood eosinophil count was ≥300 cells·µL−1 in 52.1% of adults and 73.8% of minors. By physician evaluation, 67.2% of adults and 77.2% of minors were responders and 71.1% adults and 78.5% minors had a ≥40% reduction in the exacerbation rate. In adults, the response rate for combined criteria was 58.4% (95% CI 53.2–63.4%) for blood eosinophils ≥300 cells·µL−1 (n=377) and 58.1% (95% CI 52.7–63.4%) for blood eosinophils <300 cells·µL−1 (n=346).This study shows that a large proportion of patients with SAA have a blood eosinophil count ≥300 cells·µL−1, and suggests that omalizumab effectiveness is similar in “high” and “low” eosinophil subgroups.

scholarly journals Predictors of reversible airway obstruction with omalizumab in severe asthma: a real-life study

2019 ◽  
Vol 13 ◽  
pp. 175346661984127 ◽  
Author(s):  
Paolo Solidoro ◽  
Filippo Patrucco ◽  
Francesca de Blasio ◽  
Luisa Brussino ◽  
Michela Bellocchia ◽  
...  
Keyword(s):  
Airway Obstruction ◽  
Allergic Asthma ◽  
Severe Asthma ◽  
Airway Remodeling ◽  
Real Life ◽  
Forced Expiratory Volume ◽  
Life Study ◽  
Reversible Airway Obstruction ◽  
Number Of Patients ◽  
Severe Allergic Asthma

Background: Omalizumab may modulate airway remodeling in severe asthma. Using forced expiratory volume in 1 second (FEV1) as a surrogate of airway remodeling, we aimed to investigate if an omalizumab add-on in severe allergic asthma may lead to a persistent reversal of airway obstruction and to evaluate the potential biomarkers of airway obstruction reversibility. Methods: Data were collected before (T0) and after omalizumab add-on for 1 year (T1, 32 patients), 2 years (T2, 26 patients) and 4 years (T4, 13 patients). All patients had baseline FEV1 below 80 % predicted (60.5 ± 12.5 %). After omalizumab, 18 patients showed FEV1 normalization (reversible airway obstruction; RAO+) already at T1 (88.7 ± 14.9 %, p < 0.0001) that persisted up to T4 (83.2 ± 7.9, p < 0.01), while 14 patients (RAO−) had FEV1 persistently decreased, from T1 (65.2 ± 8.4%, p < 0.05) up to T4 (61.4 ± 6.2%, not significant). Both groups had significant improvement of symptoms and exacerbations after omalizumab at T1, which persisted up to T4. The comparison between pretreatment characteristics of the two groups showed that RAO+ patients, had higher values of circulating eosinophils, exhaled nitric oxide (FENO), prevalence of rhinitis and nasal polyps, need of oral corticosteroids, shorter asthma duration, higher FEV1 and response to albuterol test. The optimal cut-off points predicting FEV1 normalization after omalizumab add-on were 30.5 ppb for FENO and 305 cells/µl for eosinophils. Conclusions: This study suggests that omalizumab add-on contributes to the persistent reversal of airway obstruction in a consistent number of patients with severe allergic asthma, and this beneficial effect is predicted by elevated pretreatment FENO and circulating eosinophils.

Long-term efficacy and safety of omalizumab in patients with allergic asthma: A real-life study

2021 ◽  
Vol 42 (3) ◽  
pp. 235-242 ◽  
Author(s):  
Andriana I. Papaioannou ◽  
Myrto Mplizou ◽  
Konstantinos Porpodis ◽  
Evangelia Fouka ◽  
Eleftherios Zervas ◽  
...  
Keyword(s):  
Lung Function ◽  
Adverse Events ◽  
Allergic Asthma ◽  
Asthma Control ◽  
Real Life ◽  
Efficacy And Safety ◽  
Life Study ◽  
Long Term Treatment ◽  
Real Life Study

Background: The efficacy and safety of omalizumab in patients with severe allergic asthma have been established in both randomized controlled trials and real-life studies. Objective: To evaluate the sustained effectiveness and safety of long-term treatment with omalizumab in a real-world setting. Methods: In this retrospective study, we included patients treated with omalizumab for at least 8 years in four asthma clinics in Greece. Pulmonary function, asthma control, oral corticosteroids (OCS) dose, and exacerbations were recorded before treatment, 6 months later, and annually thereafter. Adverse events were also recorded. Results: Forty-five patients (66.7% women), mean ± standard deviation (SD) age 55.3 ± 12.2 years, were included. The duration of treatment with omalizumab was 10.6 ± 1.2 years. The annual exacerbation rate decreased from 4.1 before omalizumab initiation to 1.1 after 1 year of treatment and remained low up to the 8th year of treatment (p < 0.001). From the 19 patients who were receiving OCS at baseline, 21.1% patients discontinued after 6 months, 47.4% were still on OCS after 4 years of therapy, and 31.6% were on OCS after 8 years. With regard to the OCS dose, 36.8% of the patients reduced the dose ≥ 50% after 6 months and 68.4% achieved 50% reduction after 2 years. The mean daily OCS dose before omalizumab initiation was 7.8 mg of prednisolone or the equivalent, reduced to 4.7 mg/day after 6 months, which reached 1.6 mg/day after 8 years (p < 0.001). Treatment with omalizumab resulted in significant improvements of asthma control and lung function. No severe adverse events were reported. Conclusion: In this real-life study, omalizumab resulted in significant and sustained improvements in asthma exacerbations, asthma control, and lung function, and had a steroid sparing effect and a good safety profile.

Long term efficacy and safety of omalizumab in patients with allergic asthma-A real life study

2020 ◽  
Author(s):  
Andriana Papaioannou ◽  
Myrto Mplizou ◽  
Konstantinos Porpodis ◽  
Evangelia Fouka ◽  
Eleftherios Zervas ◽  
...  
Keyword(s):  
Allergic Asthma ◽  
Real Life ◽  
Efficacy And Safety ◽  
Life Study ◽  
Term Efficacy ◽  
Real Life Study

Baseline data of the DEVIDE-study: DEnosumab vs Intravenous Ibandronate: a 2-year retrospective head to head real life study

2014 ◽  
Author(s):  
Karin Amrein ◽  
Christian Muschitz ◽  
Doris Wagner ◽  
Thomas R Pieber ◽  
Heinrich Resch ◽  
...  
Keyword(s):  
Real Life ◽  
Baseline Data ◽  
Life Study ◽  
Real Life Study
Sign in / Sign up

Export Citation Format

Share Document